16 commercial payer policies list J9144. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
16 policies from 14 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J9144 |
|---|---|---|
| Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Daratumumab (e.g., Darzalex) / Daratumumab and Hyaluronidase-fihj (e.g., Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Daratumumab and hyaluronidase-fihj (Darzalex Faspro) | Jul 31, 2020 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Cigna MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Daratumumab (Darzalex); CP.PHAR.310 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Q4 - 2026 JHP MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Oncology - daratumumab and daratumumab hyaluronidase-fihj (Darzalex and Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Daratumumab (Darzalex), Daratumumab and hyaluronidase-fihj (Darzalex Faspro) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9144 |
|---|---|---|
| Darzalex Faspro (daratumumab and hyaluronidase-fihj) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |